CPRX - Catalyst Pharma nabs new U.S. patents for Firdapse

United States Patent and Trademark Office issued a new U.S. patent to Catalyst Pharmaceuticals (CPRX) for Firdapse (amifampridine), Patent No. 10,793,893, Methods of Administering 3,4-Diaminopyridine; expires on April 7, 2034.“This patent is directed to innovative methods of administering amifampridine to slow metabolizers of amifampridine,” commented Steven Miller, COO and Chief Scientific OfficerThe company plans to submit a request for this patent be listed in on FDA’s Orange Book.

For further details see:

Catalyst Pharma nabs new U.S. patents for Firdapse